Archives
Verapamil HCl: Atomic Insights into L-type Calcium Channe...
Verapamil HCl: Atomic Insights into L-type Calcium Channel Blockade
Executive Summary: Verapamil HCl is a phenylalkylamine L-type calcium channel blocker with high solubility in DMSO (≥14.45 mg/mL), water (≥6.41 mg/mL, ultrasonic), and ethanol (≥8.95 mg/mL, ultrasonic) (APExBIO). It modulates calcium influx and inhibits P-glycoprotein-mediated drug efflux, thereby potentiating the intracellular retention and effect of apoptosis inducers in myeloma and leukemia cell lines (Grujić & Renko 2002). Verapamil HCl has been validated in vivo for reducing pro-inflammatory cytokine mRNA (IL-1β, IL-6, NOS-2, COX-2) and arthritis severity in CIA mouse models. The compound is integral to workflows dissecting calcium signaling, drug resistance, and apoptosis, with clear parameters for solubility and storage. This article extends previous guides by contrasting precise limits and optimized integration strategies for Verapamil HCl in translational research.
Biological Rationale
Verapamil HCl belongs to the phenylalkylamine class of L-type calcium channel blockers (APExBIO). Calcium channels are critical in the regulation of excitable cell function, including cardiac, neuronal, and immune cells. L-type calcium channel inhibition interrupts calcium influx, a key signal in the activation, proliferation, and survival of various cell types. Dysregulated calcium signaling is associated with diseases such as multiple myeloma, leukemia, and inflammatory arthritis (Grujić & Renko 2002). By modulating these pathways, Verapamil HCl is a valuable research tool for dissecting the molecular basis of apoptosis and inflammation.
Mechanism of Action of Verapamil HCl
Verapamil HCl exerts its effects by binding to and inhibiting L-type voltage-gated calcium channels, reducing transmembrane calcium influx (APExBIO). In addition to channel blockade, Verapamil impairs P-glycoprotein (Pgp) activity, inhibiting the efflux of chemotherapeutic agents and increasing intracellular drug concentration (Grujić & Renko 2002). This dual mechanism enhances cellular sensitivity to apoptosis, particularly in multidrug-resistant myeloma and leukemia lines. Calcium channel inhibition also disrupts signaling cascades involved in cell proliferation, ER stress, and inflammatory gene expression.
Evidence & Benchmarks
- Verapamil HCl inhibits L-type calcium channels in excitable cells, reducing calcium influx (APExBIO, product page).
- Enhances apoptotic cell death when combined with proteasome inhibitors (e.g., bortezomib) in myeloma cell lines JK-6L, RPMI8226, and ARH-77 (Grujić & Renko 2002).
- Verapamil, at 20 mg/kg intraperitoneally daily, significantly attenuates arthritis severity and reduces IL-1β, IL-6, NOS-2, and COX-2 mRNA levels in CIA mouse models (APExBIO, product page).
- Impedes P-glycoprotein (Pgp)-mediated drug efflux, increasing intracellular accumulation of bestatin and other apoptosis inducers in K562 myeloma cells (Grujić & Renko 2002).
- Verapamil HCl displays robust solubility: ≥14.45 mg/mL in DMSO, ≥6.41 mg/mL in water (ultrasonic), ≥8.95 mg/mL in ethanol (ultrasonic) (APExBIO).
Applications, Limits & Misconceptions
Verapamil HCl is widely used in experimental models of calcium channel inhibition, apoptosis induction, and inflammatory disease. In myeloma research, it serves as a sensitizer to proteasome inhibitors by increasing intracellular drug retention. In arthritis models, it reduces inflammatory gene expression and disease severity. Its use extends to cell signaling and multidrug resistance studies.
- Verapamil HCl: Translational Applications in Calcium Channel Research focuses on TXNIP pathway modulation; this article clarifies Pgp-mediated drug retention mechanisms in myeloma cells.
- Applied Workflows in Myeloma and Arthritis details protocols for apoptosis and inflammation; here, we update with atomic solubility, storage, and drug resistance insights.
- Atomic Insights into Calcium Channel Blockade provides molecular mechanism overviews; this article enumerates tested model conditions and benchmarks for translational use.
Common Pitfalls or Misconceptions
- Verapamil HCl does not directly inhibit all classes of calcium channels; it is specific for L-type channels.
- Its potentiation of apoptosis is contingent on co-treatment with other apoptosis inducers; Verapamil alone has limited effect on cell death (Grujić & Renko 2002).
- Verapamil's effect on drug efflux is largely limited to cells expressing functional P-glycoprotein (Pgp); efficacy may be reduced in Pgp-negative lines.
- Degradation in solution may occur rapidly at room temperature; immediate use after dissolution and storage at -20°C is essential (APExBIO).
- In vivo anti-inflammatory effects have been validated primarily in collagen-induced arthritis models; generalization to other inflammation models requires further evidence.
Workflow Integration & Parameters
Verapamil HCl is provided as a solid and is highly soluble (≥14.45 mg/mL in DMSO; ≥6.41 mg/mL in water and ≥8.95 mg/mL in ethanol with ultrasonic assistance). For cell-based assays, prepare fresh solutions and use immediately to prevent degradation. Store powder at -20°C. In apoptosis studies, co-treat myeloma cells with Verapamil (typically 2-10 μM) and apoptosis inducers, monitoring caspase 3/7 activation as a readout (Grujić & Renko 2002). In inflammatory models, an intraperitoneal dose of 20 mg/kg daily is recommended for CIA mouse models. For drug resistance studies, use in parallel with efflux-sensitive agents to evaluate Pgp-mediated retention.
For translational guidance and troubleshooting, see Unlocking Calcium Channel Blockade for Translational Research, which is complemented here by a focus on mechanistic benchmarks and validated dose parameters.
Conclusion & Outlook
Verapamil HCl, as offered by APExBIO, is a robust, well-validated L-type calcium channel blocker with clear solubility, storage, and experimental parameters. It enables precise interrogation of calcium signaling, apoptosis, and inflammation mechanisms in both in vitro and in vivo systems. The compound's dual inhibition of calcium channels and P-glycoprotein positions it as a critical tool in multidrug resistance and apoptosis research. Future work will refine its translational applications across disease models, leveraging its atomic, benchmarked properties for reproducible, mechanistic studies.